Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Comment by wizzdumbon May 11, 2023 10:00am
76 Views
Post# 35442913

RE:New Press Release - Microbix Reports Results for Q2 Fiscal 2023

RE:New Press Release - Microbix Reports Results for Q2 Fiscal 2023Snoozefest as expected. Antigens roaring back. Zero VTM in first half is concerning. QAPs stuck in the mud while we wait for any announcement. Now getting close to halfway through third quarter and still nada. I'm starting to question how it's possible that third and fourth quarter results are going to so much better without new big partnerships in place as they will take time to ramp. We all understand timing is difficult to predict but this is starting to get ridiculous. Same comment on Kinlytic. It's obvious the market has given up and if this goes on much longer even the optimistic will need to reconsider. Get a deal done team, any deal. 
<< Previous
Bullboard Posts
Next >>